S&P 500   3,947.35 (+1.18%)
DOW   31,759.82 (+1.59%)
QQQ   291.75 (+1.06%)
AAPL   142.17 (+3.33%)
MSFT   259.85 (+2.89%)
FB   194.33 (+0.41%)
GOOGL   2,223.33 (+2.07%)
AMZN   2,109.38 (-1.97%)
TSLA   668.52 (+0.70%)
NVDA   166.58 (-0.22%)
BABA   86.74 (-0.06%)
NIO   15.66 (-4.74%)
AMD   93.46 (-0.04%)
CGC   5.23 (-5.25%)
MU   69.13 (+0.33%)
T   20.83 (+2.11%)
GE   75.79 (+0.72%)
F   12.82 (+2.56%)
DIS   104.87 (+2.39%)
AMC   11.63 (-3.33%)
PFE   53.05 (+1.11%)
PYPL   81.01 (+0.58%)
NFLX   184.27 (-1.12%)
S&P 500   3,947.35 (+1.18%)
DOW   31,759.82 (+1.59%)
QQQ   291.75 (+1.06%)
AAPL   142.17 (+3.33%)
MSFT   259.85 (+2.89%)
FB   194.33 (+0.41%)
GOOGL   2,223.33 (+2.07%)
AMZN   2,109.38 (-1.97%)
TSLA   668.52 (+0.70%)
NVDA   166.58 (-0.22%)
BABA   86.74 (-0.06%)
NIO   15.66 (-4.74%)
AMD   93.46 (-0.04%)
CGC   5.23 (-5.25%)
MU   69.13 (+0.33%)
T   20.83 (+2.11%)
GE   75.79 (+0.72%)
F   12.82 (+2.56%)
DIS   104.87 (+2.39%)
AMC   11.63 (-3.33%)
PFE   53.05 (+1.11%)
PYPL   81.01 (+0.58%)
NFLX   184.27 (-1.12%)
S&P 500   3,947.35 (+1.18%)
DOW   31,759.82 (+1.59%)
QQQ   291.75 (+1.06%)
AAPL   142.17 (+3.33%)
MSFT   259.85 (+2.89%)
FB   194.33 (+0.41%)
GOOGL   2,223.33 (+2.07%)
AMZN   2,109.38 (-1.97%)
TSLA   668.52 (+0.70%)
NVDA   166.58 (-0.22%)
BABA   86.74 (-0.06%)
NIO   15.66 (-4.74%)
AMD   93.46 (-0.04%)
CGC   5.23 (-5.25%)
MU   69.13 (+0.33%)
T   20.83 (+2.11%)
GE   75.79 (+0.72%)
F   12.82 (+2.56%)
DIS   104.87 (+2.39%)
AMC   11.63 (-3.33%)
PFE   53.05 (+1.11%)
PYPL   81.01 (+0.58%)
NFLX   184.27 (-1.12%)
S&P 500   3,947.35 (+1.18%)
DOW   31,759.82 (+1.59%)
QQQ   291.75 (+1.06%)
AAPL   142.17 (+3.33%)
MSFT   259.85 (+2.89%)
FB   194.33 (+0.41%)
GOOGL   2,223.33 (+2.07%)
AMZN   2,109.38 (-1.97%)
TSLA   668.52 (+0.70%)
NVDA   166.58 (-0.22%)
BABA   86.74 (-0.06%)
NIO   15.66 (-4.74%)
AMD   93.46 (-0.04%)
CGC   5.23 (-5.25%)
MU   69.13 (+0.33%)
T   20.83 (+2.11%)
GE   75.79 (+0.72%)
F   12.82 (+2.56%)
DIS   104.87 (+2.39%)
AMC   11.63 (-3.33%)
PFE   53.05 (+1.11%)
PYPL   81.01 (+0.58%)
NFLX   184.27 (-1.12%)
NASDAQ:PCRX

Pacira BioSciences (PCRX) Stock Forecast, Price & News

$64.32
+0.73 (+1.15%)
(As of 05/23/2022 01:07 PM ET)
Add
Compare
Today's Range
$63.26
$64.55
50-Day Range
$59.51
$81.64
52-Week Range
$45.05
$82.16
Volume
6,833 shs
Average Volume
541,323 shs
Market Capitalization
$2.92 billion
P/E Ratio
76.57
Dividend Yield
N/A
Beta
0.88
30 days | 90 days | 365 days | Advanced Chart
Receive PCRX News and Ratings via Email

Sign-up to receive the latest news and ratings for Pacira BioSciences and its competitors with MarketBeat's FREE daily newsletter.

Pacira BioSciences logo

About Pacira BioSciences

Pacira BioSciences, Inc. provides non-opioid pain management and regenerative health solutions for healthcare practitioners and their patients in the United States. The company offers EXPAREL, a bupivacaine liposome injectable suspension; ZILRETTA, a triamcinolone acetonide extended-release injectable suspension; and iovera system, a non-opioid handheld cryoanalgesia device used to produce controlled doses of cold temperature only to targeted nerves. It also develops proprietary multivesicular liposome, a drug delivery technology that encapsulates drugs without altering their molecular structure. The company was formerly known as Pacira Pharmaceuticals, Inc. and changed its name to Pacira BioSciences, Inc. in April 2019. Pacira BioSciences, Inc. was incorporated in 2006 and is headquartered in Tampa, Florida.

Headlines

See More Headlines

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
Pharmaceuticals
Sector
Medical
Current Symbol
NASDAQ:PCRX
CUSIP
69512710
Employees
697
Year Founded
N/A

Sales & Book Value

Annual Sales
$541.53 million
Cash Flow
$3.61 per share
Book Value
$15.62 per share

Profitability

Net Income
$41.98 million
Pretax Margin
8.78%

Debt

Price-To-Earnings

Miscellaneous

Free Float
43,074,000
Market Cap
$2.92 billion
Optionable
Optionable

Company Calendar

Last Earnings
5/04/2022
Today
5/23/2022
Next Earnings (Estimated)
8/02/2022
Fiscal Year End
12/31/2022

MarketRank

Overall MarketRank

2.17 out of 5 stars

Medical Sector

399th out of 1,416 stocks

Pharmaceutical Preparations Industry

162nd out of 677 stocks

Analyst Opinion: 3.4Community Rank: 4.8Dividend Strength: 0.0Insider Behavior: 0.8Valuation: 1.9 5 -4 -3 -2 -1 -













Pacira BioSciences (NASDAQ:PCRX) Frequently Asked Questions

Is Pacira BioSciences a buy right now?

7 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Pacira BioSciences in the last twelve months. There are currently 2 hold ratings and 5 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Pacira BioSciences stock.
View analyst ratings for Pacira BioSciences
or view top-rated stocks.

When is Pacira BioSciences' next earnings date?

Pacira BioSciences is scheduled to release its next quarterly earnings announcement on Tuesday, August 2nd 2022.
View our earnings forecast for Pacira BioSciences
.

How were Pacira BioSciences' earnings last quarter?

Pacira BioSciences, Inc. (NASDAQ:PCRX) released its quarterly earnings data on Wednesday, May, 4th. The company reported $0.64 earnings per share for the quarter, missing the consensus estimate of $0.83 by $0.19. The business earned $157.99 million during the quarter, compared to the consensus estimate of $155.08 million. Pacira BioSciences had a net margin of 6.62% and a trailing twelve-month return on equity of 15.17%. The firm's quarterly revenue was up 32.7% on a year-over-year basis. During the same period in the prior year, the company earned $0.37 EPS.
View Pacira BioSciences' earnings history
.

What guidance has Pacira BioSciences issued on next quarter's earnings?

Pacira BioSciences updated its first quarter 2022 earnings guidance on Tuesday, April, 26th. The company provided EPS guidance of for the period. The company issued revenue guidance of $157.40 million-$158.40 million, compared to the consensus revenue estimate of $162.85 million.

What price target have analysts set for PCRX?

7 equities research analysts have issued 12-month price objectives for Pacira BioSciences' stock. Their forecasts range from $60.00 to $96.00. On average, they expect Pacira BioSciences' share price to reach $82.00 in the next year. This suggests a possible upside of 27.7% from the stock's current price.
View analysts' price targets for Pacira BioSciences
or view top-rated stocks among Wall Street analysts.

Who are Pacira BioSciences' key executives?
Pacira BioSciences' management team includes the following people:
What is Dave Stack's approval rating as Pacira BioSciences' CEO?

54 employees have rated Pacira BioSciences CEO Dave Stack on Glassdoor.com. Dave Stack has an approval rating of 45% among Pacira BioSciences' employees. This puts Dave Stack in the bottom 10% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Pacira BioSciences own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Pacira BioSciences investors own include Gilead Sciences (GILD), NVIDIA (NVDA), Micron Technology (MU), ACADIA Pharmaceuticals (ACAD), Skyworks Solutions (SWKS), AbbVie (ABBV), Pfizer (PFE), QUALCOMM (QCOM), Exelixis (EXEL) and Tesla (TSLA).

What is Pacira BioSciences' stock symbol?

Pacira BioSciences trades on the NASDAQ under the ticker symbol "PCRX."

Who are Pacira BioSciences' major shareholders?

Pacira BioSciences' stock is owned by a number of retail and institutional investors. Top institutional investors include Vanguard Group Inc. (10.32%), Baillie Gifford & Co. (4.68%), Renaissance Technologies LLC (4.10%), Loomis Sayles & Co. L P (2.85%), Stephens Investment Management Group LLC (2.56%) and Clearbridge Investments LLC (2.48%). Company insiders that own Pacira BioSciences stock include Andreas Wicki, Anthony Molloy, Charles A Reinhart III, Charles Anthony Laranjeira, David M Stack, David M Stack, Donald C Manning, Gary W Pace, John P Phd Longenecker, Kristen Marie Williams, Laura Brege, Lauren Bullaro Riker, Mark Froimson, Max Reinhardt, Paul J Hastings and Roy Winston.
View institutional ownership trends for Pacira BioSciences
.

Which institutional investors are selling Pacira BioSciences stock?

PCRX stock was sold by a variety of institutional investors in the last quarter, including JPMorgan Chase & Co., Paulson & CO. Inc., Rock Springs Capital Management LP, Zurcher Kantonalbank Zurich Cantonalbank , Goldman Sachs Group Inc., Baillie Gifford & Co., AIA Group Ltd, and Candriam Luxembourg S.C.A.. Company insiders that have sold Pacira BioSciences company stock in the last year include Anthony Molloy, Charles A Reinhart III, David M Stack, Donald C Manning, Gary W Pace, John P Phd Longenecker, Kristen Marie Williams, Lauren Bullaro Riker, Mark Froimson, Max Reinhardt, and Roy Winston.
View insider buying and selling activity for Pacira BioSciences
or view top insider-selling stocks.

Which institutional investors are buying Pacira BioSciences stock?

PCRX stock was bought by a variety of institutional investors in the last quarter, including Wellington Management Group LLP, Emerald Advisers LLC, Emerald Mutual Fund Advisers Trust, Lisanti Capital Growth LLC, Russell Investments Group Ltd., New York State Common Retirement Fund, Frontier Capital Management Co. LLC, and Loomis Sayles & Co. L P.
View insider buying and selling activity for Pacira BioSciences
or or view top insider-buying stocks.

How do I buy shares of Pacira BioSciences?

Shares of PCRX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Pacira BioSciences' stock price today?

One share of PCRX stock can currently be purchased for approximately $64.20.

How much money does Pacira BioSciences make?

Pacira BioSciences has a market capitalization of $2.92 billion and generates $541.53 million in revenue each year. The company earns $41.98 million in net income (profit) each year or $0.839990 on an earnings per share basis.

How many employees does Pacira BioSciences have?

Pacira BioSciences employs 697 workers across the globe.

What is Pacira BioSciences' official website?

The official website for Pacira BioSciences is www.pacira.com.

How can I contact Pacira BioSciences?

Pacira BioSciences' mailing address is 5 SYLVAN WAY SUITE 300, PARSIPPANY NJ, 07054. The company can be reached via phone at (813) 553-6680, via email at [email protected], or via fax at 302-655-5049.

This page was last updated on 5/23/2022 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.